Atlas Trials

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Clinical trial NCT02943473 · TERMINATED

Trial details

NCT number
NCT02943473
Sponsor
Icahn School of Medicine at Mount Sinai
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
High Risk Smoldering Multiple Myeloma
Start date
2017-05-18
Primary completion
2019-09-10
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.